First-phase parameters in hepatitis C viral kinetics

被引：4
作者：
Zeuzem, S
Herrmann, E
机构：
[1] Univ Hosp Homburg Saar, Dept Med, Div Gastroenterol Hepatol & Endocrinol, Homburg, Germany
[2] Darmstadt Univ Techno, Dept Math, Darmstadt, Germany
来源：
JOURNAL OF VIRAL HEPATITIS | 2002年 / 9卷 / 05期
关键词：
D O I：
10.1046/j.1365-2893.2002.00375.x
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：332 / 333
页数：2
相关论文
共 13 条
[1]   Pegylated (40 kDa) interferon alfa-2a (PEGASYS®) in combination with ribavirin:: Efficacy and safety results from a phase III, randomized, actively-controlled, multicenter study [J].
Fried, MW ;
Shiffman, ML ;
Reddy, RK ;
Smith, C ;
Marino, G ;
Goncales, F ;
Haeussinger, D ;
Diago, M ;
Carosi, G ;
Zarski, JP ;
Hoffman, J ;
Yu, J .
GASTROENTEROLOGY, 2001, 120 (05) :A55-A55
[2]  
Lam NP, 1997, HEPATOLOGY, V26, P226
[3]   First phase viral kinetic parameters as predictors of treatment response and their influence on the second phase viral decline [J].
Layden, JE ;
Layden, TJ ;
Reddy, KR ;
Levy-Drummer, RS ;
Poulakos, J ;
Neumann, AU .
JOURNAL OF VIRAL HEPATITIS, 2002, 9 (05) :340-345
[4]   Induction therapy with consensus interferon (CIFN) does not improve sustained virologic response in chronic hepatitis C [J].
Layden, TJ ;
Layden, JE ;
Reddy, KR ;
Levy-Drummer, RS ;
Poulakos, J ;
Neumann, AU .
JOURNAL OF VIRAL HEPATITIS, 2002, 9 (05) :334-339
[5]   Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial [J].
Manns, MP ;
McHutchison, JG ;
Gordon, SC ;
Rustgi, VK ;
Shiffman, M ;
Reindollar, R ;
Goodman, ZD ;
Koury, K ;
Ling, MH ;
Albrecht, JK .
LANCET, 2001, 358 (9286) :958-965
[6]   Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C [J].
McHutchison, JG ;
Gordon, SC ;
Schiff, ER ;
Shiffman, ML ;
Lee, WM ;
Rustgi, VK ;
Goodman, ZD ;
Ling, MH ;
Cort, S ;
Albrecht, JK .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (21) :1485-1492
[7]  
Neumann AU, 1999, HEPATOLOGY, V30, p309A
[8]   Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-α therapy [J].
Neumann, AU ;
Lam, NP ;
Dahari, H ;
Gretch, DR ;
Wiley, TE ;
Layden, TJ ;
Perelson, AS .
SCIENCE, 1998, 282 (5386) :103-107
[9]   Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus [J].
Poynard, T ;
Marcellin, P ;
Lee, SS ;
Niederau, C ;
Minuk, GS ;
Ideo, G ;
Bain, V ;
Heathcote, J ;
Zeuzem, S ;
Trepo, C ;
Albrecht, J .
LANCET, 1998, 352 (9138) :1426-1432
[10]   Peginterferon alfa-2a in patients with chronic hepatitis C [J].
Zeuzem, S ;
Feinman, SV ;
Rasenack, J ;
Heathcote, EJ ;
Lai, MY ;
Gane, E ;
O'Grady, J ;
Reichen, J ;
Diago, M ;
Lin, A ;
Hoffman, J ;
Brunda, MJ .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (23) :1666-1672
12